Objective:To investigate the effect of enalapril on plasma homocysteine(Hcy) levels and the association of methylenetetrahydrofolate reductase(MTHFR) C677T polymorphism with the changes of Hcy levels in response to en...Objective:To investigate the effect of enalapril on plasma homocysteine(Hcy) levels and the association of methylenetetrahydrofolate reductase(MTHFR) C677T polymorphism with the changes of Hcy levels in response to enalapril among patients with essential hypertension.Methods:A total of 130 patients with mild-to-moderate essential hypertension were enrolled and enalapril was orally administered at a dose of 10 mg/d for eight weeks.Plasma Hcy levels were measured by denaturing high-performance liquid chromatography(DHPLC) at baseline and after eight weeks of treatment.Genotyping of MTHFR C677T polymorphism was performed by TaqMan probe technique.Results:Compared with baseline,plasma Hcy levels did not change significantly after eight weeks(P=0.81).Stratified by baseline Hcy levels,a significant increase in plasma Hcy levels(P=0.02) among those with Hcy <10 μmol/L was observed,in contrast to no significant changes in plasma Hcy levels(P=0.54) among those with Hcy ≥10 μmol/L.No significant association was observed between MTHFR C677T polymorphism and changes in Hcy levels in response to enalapril.Conclusions:Enalapril may cause an increase in plasma Hcy levels among the hypertensives with low baseline Hcy levels.There was no significant association between MTHFR C677T genotypes and changes in Hcy levels in response to enalapril among subjects with essential hypertension.展开更多
文摘目的系统评价马来酸依那普利叶酸片治疗H型高血压的临床疗效和安全性。方法计算机检索CNKI、维普、万方、Pub Med、Medline、EMbase和相关数据库,辅以文献追溯、网上查询等方法,检索建库至2015年5月31日国内外公开发表的马来酸依那普利叶酸片治疗H型高血压随机对照研究,采用Rev Man 5.0软件进行定量综合分析。结果共纳入17篇对照研究,合计H型高血压患者2 323例。其中14项研究介绍了SBP改变情况,结果显示：WMD=-6.73,95%CI：-10.13--3.39,Z=3.93,P〈0.05;14项研究介绍了DBP改变情况,结果显示：WMD=-6.76,95%CI：-10.23--2.51,Z=5.96,P〈0.05;17项研究介绍了Hcy改变情况,结果显示：WMD=-4.18,95%CI：-6.58--3.03,Z=5.32,P〈0.05;7项研究介绍了心脑血管事件发生情况,结果显示：OR=0.28,95%CI：0.18-0.43,Z=5.96,P〈0.05。常见不良反应无显著性差异。结论马来酸依那普利叶酸片治疗H型高血压的疗效和安全性优于马来酸依那普利。
文摘Objective:To investigate the effect of enalapril on plasma homocysteine(Hcy) levels and the association of methylenetetrahydrofolate reductase(MTHFR) C677T polymorphism with the changes of Hcy levels in response to enalapril among patients with essential hypertension.Methods:A total of 130 patients with mild-to-moderate essential hypertension were enrolled and enalapril was orally administered at a dose of 10 mg/d for eight weeks.Plasma Hcy levels were measured by denaturing high-performance liquid chromatography(DHPLC) at baseline and after eight weeks of treatment.Genotyping of MTHFR C677T polymorphism was performed by TaqMan probe technique.Results:Compared with baseline,plasma Hcy levels did not change significantly after eight weeks(P=0.81).Stratified by baseline Hcy levels,a significant increase in plasma Hcy levels(P=0.02) among those with Hcy <10 μmol/L was observed,in contrast to no significant changes in plasma Hcy levels(P=0.54) among those with Hcy ≥10 μmol/L.No significant association was observed between MTHFR C677T polymorphism and changes in Hcy levels in response to enalapril.Conclusions:Enalapril may cause an increase in plasma Hcy levels among the hypertensives with low baseline Hcy levels.There was no significant association between MTHFR C677T genotypes and changes in Hcy levels in response to enalapril among subjects with essential hypertension.
